SGP
SpyGlass Pharma, Inc.
23.90$
-3.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|
| 0.00 | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| – | – | – | – | 0.01 | 0.02 | 0.01 | – | |
| – | – | – | – | -0.01 | -0.02 | -0.01 | – | |
| 0.18 | – | – | 0.24 | 0.23 | 0.41 | 0.32 | 1.04 | |
| 0.06 | – | – | 0.09 | 0.18 | 0.34 | 0.33 | 0.80 | |
| 0.24 | – | – | 0.33 | 0.40 | 0.76 | 0.65 | 1.83 | |
| -0.24 | – | – | -0.33 | -0.41 | -0.77 | -0.66 | -1.86 | |
| -0.26 | – | – | -0.29 | -0.38 | -0.69 | -0.59 | -1.68 | |
| -0.26 | – | – | -0.29 | -0.38 | -0.69 | -0.59 | -1.68 | |
| – | – | – | -0.33 | -0.37 | -0.68 | -0.65 | -1.75 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.